Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1) receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety profile comparable to other anti–PD-1 therapies. This population pharmacokinetics (PopPK) analysis of cemiplimab included 11,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Feng, Paccaly, Anne J., Rippley, Ronda K., Davis, John D., DiCioccio, A. Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225544/
https://www.ncbi.nlm.nih.gov/pubmed/33728546
http://dx.doi.org/10.1007/s10928-021-09739-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225544/
https://www.ncbi.nlm.nih.gov/pubmed/33728546
http://dx.doi.org/10.1007/s10928-021-09739-y

Ejemplares similares